MS-STAT2 trial results
Sept 2024: The results of the MS-STAT2 trial were announced by Professor Jeremy Chataway at the ECTRIMS research conference on 20th September.
The Anne Rowling Clinic was the main recruitment site in Scotland for the MS-STAT2 clinical drug trial. This phase 3 trial tested simvastatin, which is commonly used to treat high cholesterol, in 964 people with secondary progressive MS. The results of the MS-STAT2 trial were announced by Professor Jeremy Chataway at the ECTRIMS research conference in Copenhagen on 20th September.
The results of the trial showed that simvastatin is not able to slow disability progression in people with secondary progressive MS. Although this is disappointing news for participants, this trial has increased the understanding of the biology of progressive MS.
We're grateful to all the participants whom took part in the trial, without who research like this wouldn't be possible.
For the full news article and video message by Professor Chataway please visit the MS Society website (external website)